Ahmed Salem1, Peng Men2,3, Mafalda Ramos4, Yan-Jun Zhang5, Anastasia Ustyugova6, Mark Lamotte7. 1. IQVIA, Real World Solutions, Zaventem 1930, Belgium. 2. Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China. 3. Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China. 4. IQVIA, Global HEOR, Porto Salvo 2740-266, Portugal. 5. Boehringer Ingelheim, Health Economics & Outcomes Research, Government Affairs & Market Access, Shanghai 200040, China. 6. Boehringer Ingelheim, CardioMetabolism Respiratory, Ingelheim am Rhein 55216, Germany. 7. IQVIA, Global HEOR, Zaventem 1930, Belgium.
Abstract
Aim: The study assesses the cost-effectiveness of empagliflozin versus glimepiride in patients with Type 2 diabetes and uncontrolled by metformin alone in China, based on the EMPA-REG H2H-SU trial. Materials & methods: A calibrated version of the IQVIA Core Diabetes Model was used. Cost of complications and utility were taken from literature. The Chinese healthcare system perspective and 5% discounting rates were applied. Results: Empagliflozin+metformin provides additional quality-adjusted life-years (0.317) driven by a reduction in the number of cardiovascular and renal events, for an additional cost of $1382 (CNY9703) compared with glimepiride+metformin. Conclusion: Empagliflozin is cost-effective treatment versus glimepiride applying a threshold of $30,290 (CNY212,676).
Aim: The study assesses the cost-effectiveness of empagliflozin versus glimepiride in patients with Type 2 diabetes and uncontrolled by metformin alone in China, based on the EMPA-REGH2H-SU trial. Materials & methods: A calibrated version of the IQVIA Core Diabetes Model was used. Cost of complications and utility were taken from literature. The Chinese healthcare system perspective and 5% discounting rates were applied. Results:Empagliflozin+metformin provides additional quality-adjusted life-years (0.317) driven by a reduction in the number of cardiovascular and renal events, for an additional cost of $1382 (CNY9703) compared with glimepiride+metformin. Conclusion:Empagliflozin is cost-effective treatment versus glimepiride applying a threshold of $30,290 (CNY212,676).